I am not stating this is the case in PF-06939926 , but it is FDA structure.
In practice, clinical testing progression and design has become increasingly flexible as the science of clinical trials has evolved. Phase 1 might be combined with phase 2 if the drug is expected to have toxicity unacceptable for healthy volunteers. If the product’s mechanism of action and safety profile are well characterized, phase 2 testing may be shortened or skipped altogether. When there is sufficient evidence that a change in a biomarker reliably predicts a clinical benefit, the biomarker can serve as a surrogate measure for that clinical benefit in a trial, and the effect of the product on the surrogate measure can be a basis for product approval. Surrogate measures are often biomarkers that help diagnose or monitor a disease, such as blood pressure to predict stroke risk or the amount of human immunodeficiency virus in the blood to predict the development of acquired immunodeficiency syndrome
- Forums
- ASX - By Stock
- Ann: Trial Met Primary & Exceeded Secondary Endpoint Expectations
I am not stating this is the case in PF-06939926 , but it is FDA...
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
11.0¢ |
Change
0.010(10.0%) |
Mkt cap ! $99.16M |
Open | High | Low | Value | Volume |
11.0¢ | 11.5¢ | 10.5¢ | $160.3K | 1.467M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 577880 | 10.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
11.0¢ | 114554 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 377880 | 0.105 |
10 | 617909 | 0.100 |
3 | 113179 | 0.099 |
1 | 13000 | 0.098 |
2 | 130927 | 0.097 |
Price($) | Vol. | No. |
---|---|---|
0.110 | 114554 | 3 |
0.115 | 418332 | 5 |
0.120 | 640768 | 12 |
0.125 | 510429 | 3 |
0.130 | 298000 | 3 |
Last trade - 11.46am 30/09/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |